Tiny Health Is Building the Microbiome Intelligence Layer

Tiny Health is a San Francisco health technology company that turns at-home gut and vaginal samples into microbiome reports for families, adults, practitioners, wellness brands, and researchers. Founder and CEO Cheryl Sew Hoy launched the company in 2020 after searching for better answers about her child's eczema and food sensitivities.

What began as a test for mothers and babies now spans every life stage. Tiny Health combines direct-to-consumer testing with practitioner infrastructure, longitudinal data, clinical research, and an emerging artificial intelligence layer. That expansion matters because microbiome testing has no shortage of biological detail. The harder problem is deciding which detail deserves action.

Tiny Health enters that problem with company-reported traction of nearly 200,000 customers and more than 6,000 practitioners. Its September 2026 Series B added $33 million, bringing total funding to $46 million, while the company committed $5 million to research. The broader bet is that microbiome testing can move from an interesting report to a repeatable health intelligence system without pretending the science is finished.

About Tiny Health

Sew Hoy founded Tiny Health after two different birth experiences and her first child's health issues pushed her into the microbiome literature. At the time, consumer gut tests were built primarily for adults. She saw an unmet need for age-specific reference ranges and guidance during the first 1,000 days, when the infant microbiome changes rapidly.

Tiny Health initially focused on baby and maternal tests. Its current portfolio includes baby, child, adult, pregnancy, and vaginal microbiome products. Samples are processed through a CLIA-certified and CAP-accredited laboratory partner, while reports use shotgun metagenomic sequencing to identify organisms and functional signals.

The company is careful about an important boundary: its tests are not diagnostic, do not treat disease, and do not replace medical care. That restraint is not legal wallpaper. It defines the commercial challenge. A report can be technically detailed and still leave a family or clinician uncertain about the next decision.

The Platform Behind the Test

Tiny Health is building beyond a consumer kit. Powered by Tiny provides microbiome testing, analytics, and research infrastructure to practitioners, health companies, and research partners. Beauty Independent reports that the business-to-business operation contributes roughly half of company revenue and grew fourfold over the prior year, based on company figures.

The platform strategy has four parts. Consumer and practitioner testing generate longitudinal data. Enterprise relationships widen distribution. Research programs test which signals matter. TinyAI and new metrics such as Gut Microbiome Age and Gut Resilience aim to make the resulting information easier to interpret.

Each part depends on the others. More samples can make comparison models richer, but volume alone does not establish clinical meaning. Artificial intelligence can organize evidence and personalize explanations, but it cannot turn an association into a proven intervention. Practitioner adoption can increase reach, but only if clinicians trust the analysis and understand its limits.

Evidence Is the Product Roadmap

Tiny Health's research program includes studies on genetics, mold exposure, the oral-gut axis, aging, childhood allergies, and fertility. The company's $5 million research commitment makes evidence production a visible part of the operating plan.

A 2025 randomized controlled trial offers an early example. The open-label study enrolled 54 C-section-born infants and reported lower odds of atopic dermatitis in the intervention group. It also found differences in microbial composition and function. The result is promising, but the study was small, short, sponsored by Tiny Health, and relied partly on parent-reported outcomes. Several authors were employees or affiliates of the company.

Those limitations are exactly why the research roadmap matters. The microbiome category has spent years producing correlations that sound impressive but do not always tell a clinician what to do. Tiny Health's opportunity is to use its growing dataset to generate questions, run stronger studies, and separate useful signals from attractive noise. Independent replication will matter as much as product velocity.

Leadership and Hiring Momentum

Sew Hoy leads a team that now has to operate across consumer health, laboratory workflows, software, data science, clinical research, and practitioner distribution. Donald Koo serves as chief technology officer, Kimberley Sukhum leads research and development, Elisa Song is chief medical officer, and Taylor Sittler is chief business officer.

Tiny Health's current job board listed 21 roles on September 29, 2026. Openings included a director of clinical research, lab manager, microbiome data scientist, AI engineer, VP of engineering, technical product manager for AI and data, VP of finance, and several practitioner-facing commercial roles.

That hiring mix is more informative than a generic claim that the company is growing. Tiny Health is adding the functions required to make research, product quality, financial control, and clinician distribution scale together. Its AI Engineer listing emphasizes grounded answers, traceable sources, evaluation systems, and production reliability. Those priorities match the central risk of the category: a confident interface can make uncertain science look settled.

What Tiny Health Signals for Digital Health

Tiny Health represents a broader shift in consumer health technology. The first generation of products made biological data accessible. The next generation has to make it interpretable, longitudinal, and credible enough to fit into real decisions.

The company's reported traction suggests that consumers and practitioners want more visibility into the microbiome. Its enterprise growth suggests that testing is becoming infrastructure for other health businesses, not only a product sold one kit at a time. Its research investment acknowledges that distribution without evidence can build a large audience faster than it builds trust.

Tiny Health's durable advantage will not be the prettiest report or the largest menu of microbes. It will be the ability to make data, research, practitioner use, and responsible interpretation reinforce one another. The company is hiring across the exact seams where that system can break. That makes Tiny Health worth watching, not because microbiome science has reached certainty, but because the company is building as if earning certainty is part of the product.